Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech expects two advisory committee reviews

Executive Summary

Genentech is hoping for third quarter FDA advisory committee review of Raptiva (efalizumab) for moderate to severe plaque psoriasis in patients 18 and older, firm says during investor meeting March 14. BLA for the recombinant humanized monoclonal antibody was filed by Genentech and XOMA in December. Firm also expects Pulmonary-Allergy Drugs Advisory Committee review of Xolair (omalizumab) for moderate to severe allergic asthma in patients 12 and older ahead of an expected action date on the application by mid-year...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS041434

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel